Charles River Laboratories International, Inc. (NYSE: CRL)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001100682
Market Cap 7.88 Bn
P/E -54.85
P/S 1.96
Div. Yield 0.00
ROIC (Qtr) 0.00
Total Debt (Qtr) 2.14 Bn
Revenue Growth (1y) (Qtr) -0.83
Add ratio to table...

About

Charles River Laboratories International, Inc. is a leading global provider of non‑clinical drug development services and products. The company supports clients from early‑stage discovery through safety assessment and manufacturing by offering research models, associated services, discovery and safety testing, and microbial and biologics solutions. Its integrated portfolio enables pharmaceutical and biotechnology firms to accelerate drug development while reducing costs and improving efficiency. The company generates revenue primarily through...

Read more

Investment thesis

Bull case

  • Charles River’s strategic review has clarified a clear path to higher-margin growth by sharpening its portfolio around core science and eliminating non‑core assets that account for roughly 7% of revenue. The anticipated divestitures are projected to lift annualized earnings per share by at least 30¢ and remove legacy cost drag, thereby freeing capital that can be deployed into high‑velocity sectors such as cell and gene therapy (CGT) and new approach methodologies (NAMS). As the company pursues these sales, management has expressed confidence that the proceeds will be reinvested in capabilities that complement its existing strengths, further bolstering its market leadership.
  • The company’s third‑quarter results demonstrate a resilient demand environment, with preclinical RMS and DSA booking activity returning to or exceeding last year’s levels after a summer dip. Small and midsized biotech clients, which have historically been a growth lever, are beginning to re‑allocate budgets toward IND‑enabling work, as evidenced by a steady rise in proposal activity and a gradual normalization of cancellation rates. This uptick signals that the market is starting to recover from the funding freeze that has lingered for much of the past two years, and the trajectory is likely to continue into 2026.
  • In the CGT space, Charles River’s partnership with Gazi University to supply plasmid DNA and AAV production platforms represents a strategic expansion into a high‑growth niche. The collaboration addresses a critical supply bottleneck for early‑stage gene therapies and is positioned to accelerate development timelines for rare disease candidates, an area with increasing investor interest. By providing royalty‑free, animal‑free plasmids, the company not only mitigates regulatory hurdles but also positions itself as a preferred partner for academic CGT programs.
  • The launch of the Cell & Gene Therapy Incubator Program (CIP) underscores Charles River’s commitment to nurturing next‑generation therapies. Through tailored mentorship, regulatory guidance, and preferential access to its global manufacturing footprint, the program attracts innovative early‑stage companies that could generate long‑term, high‑margin contracts. The early success of CIP’s cohort, featuring advanced therapy developers and technology enablers, suggests a pipeline of potential revenue streams that will mature over the coming years.
  • The company’s focus on NAMS, supported by a newly formed scientific advisory board featuring former FDA leadership, places it at the forefront of regulatory evolution toward animal‑free testing. While full market adoption remains gradual, the early adoption of NAMS in biosimilar and immunogenicity studies signals a shift that could open substantial opportunities in the long term. By integrating next‑generation sequencing and recombinant endotoxin assays, Charles River can offer cost‑effective alternatives that resonate with clients’ increasing emphasis on ethics and speed.
Read more

Bear case

  • The company’s guidance for 2025 forecasts a 0.5% to 1.5% decline in reported revenue and a 1.5% to 2.5% decline on an organic basis, signaling an impending revenue contraction that is likely to continue into 2026. This downward trajectory underscores persistent uncertainty in client spend, particularly among small and midsized biotech firms whose budgets remain fragile in the face of volatile funding environments. The risk that this decline will deepen if capital markets remain constrained is material.
  • DSA margin pressure has already manifested in the third quarter, with a 200‑basis‑point decline relative to the previous year, driven by lower study volume and higher third‑party NHP sourcing costs. Management’s projection that the fourth quarter will see further margin erosion highlights the vulnerability of the DSA segment to pricing headwinds and the ongoing need for capital to backfill staff. The cumulative impact of these factors threatens the company’s overall profitability.
  • The company’s dependence on a handful of large biopharma clients for a significant portion of its DSA revenue introduces concentration risk. While these clients have reduced their portfolios, the recent loss of a major CDMO client in the Memphis site further exposed the firm to client churn. The potential for additional contract losses could erode revenue and place additional strain on the already thin DSA margins.
  • The NHP supply acquisition, while mitigating a key risk, introduces new operational and regulatory challenges. The company’s acquisition of K.F. (Cambodia) Ltd. will be subject to complex due diligence, integration risks, and compliance oversight, potentially diverting resources from core business activities. Any unforeseen operational hiccups could delay the expected cost savings and compromise service reliability.
  • The company’s ambitious cost‑cutting program, though projected to yield $300 million in annualized savings, also carries the risk of undercutting quality or client service. Workforce right‑sizing and procurement optimizations may result in skill gaps or slower service delivery if not carefully managed. If clients perceive a decline in service quality, it could accelerate churn and damage the firm’s competitive positioning.
Read more

Geographical Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 WAT Waters Corp /De/ 27,360.50 Bn 42.27 7,256.31 4.86 Bn
2 TMO Thermo Fisher Scientific Inc. 166.69 Bn 24.59 3.69 43.16 Bn
3 DHR Danaher Corp /De/ 116.47 Bn 31.82 4.70 18.48 Bn
4 IDXX Idexx Laboratories Inc /De 42.38 Bn 38.84 9.53 0.83 Bn
5 A Agilent Technologies, Inc. 32.06 Bn 24.90 4.54 0.30 Bn
6 IQV Iqvia Holdings Inc. 28.74 Bn 20.99 1.73 15.83 Bn
7 NTRA Natera, Inc. 27.83 Bn -121.42 11.13 0.02 Bn
8 ILMN Illumina, Inc. 21.92 Bn 25.95 4.99 1.49 Bn